Adult germ cell tumor

Summary

Adult germ cell tumor (MONDO:0044878) is a cancer and 79 clinical trials. Top therapeutic interventions include bleomycin, 2-mercaptoethanesulfonic acid, and brentuximab vedotin. A subtype of germ cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 79

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adult germ cell tumor
Mondo ID	MONDO:0044878
NCIT	C114777
UMLS	C3900101
MedGen	859695
GARD	0025915
Is cancer (heuristic)	yes

Also known as: Adult germ cell tumor · Adult germ cell tumour · germ cell tumor · germ cell tumor of adults · germ cell tumour · germ cell tumour of adults

Disease family

This is a subtype of germ cell tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › germ cell tumor › adult germ cell tumor

Related subtypes (12): fallopian tube germ cell tumor, retroperitoneal germ cell neoplasm, childhood germ cell tumor, choriocarcinoma, malignant germ cell tumor, ovarian germ cell tumor, extragonadal germ cell tumor, gonadal germ cell tumor, germinomatous germ cell tumor, germ cell tumor of the vulva, nongerminomatous germ cell tumor, germ cell benign neoplasm

Subtypes (3): adult yolk sac tumor, adult central nervous system germ cell tumor, adult teratoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 79.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	27
Not specified	23
PHASE1	16
PHASE1/PHASE2	7
PHASE3	5
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02375204	PHASE3	ACTIVE_NOT_RECRUITING	Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
NCT02582697	PHASE3	RECRUITING	Accelerated v’s Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
NCT03067181	PHASE3	RECRUITING	Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT05874063	PHASE3	RECRUITING	Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors
NCT00572572	PHASE3	COMPLETED	Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
NCT06341998	PHASE2/PHASE3	COMPLETED	Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children
NCT01873326	PHASE2	ACTIVE_NOT_RECRUITING	Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
NCT03158064	PHASE2	ACTIVE_NOT_RECRUITING	Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
NCT04804007	PHASE2	RECRUITING	Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
NCT04876456	PHASE2	ACTIVE_NOT_RECRUITING	A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
NCT05092451	PHASE1/PHASE2	RECRUITING	Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
NCT06418789	PHASE2	RECRUITING	High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors
NCT06866964	PHASE2	RECRUITING	A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy
NCT06937866	PHASE1/PHASE2	RECRUITING	Maintenance Zanzalintinib With Etoposide After HDCT in GCT
NCT07188441	PHASE2	RECRUITING	Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.
NCT00127049	PHASE2	UNKNOWN	Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors
NCT00179816	PHASE1/PHASE2	UNKNOWN	Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors
NCT00187109	PHASE1/PHASE2	COMPLETED	Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy
NCT00198172	PHASE2	TERMINATED	Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors
NCT00864318	PHASE2	COMPLETED	Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis
NCT00983398	PHASE1/PHASE2	UNKNOWN	Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
NCT01466231	PHASE2	COMPLETED	Everolimus in Refractory Testicular Germ Cell Cancer
NCT01743482	PHASE2	COMPLETED	Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors
NCT01782339	PHASE2	COMPLETED	A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis
NCT01966913	PHASE1/PHASE2	UNKNOWN	Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors
NCT02161692	PHASE2	COMPLETED	Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors
NCT02340884	PHASE2	COMPLETED	A Pilot RCT of the PRISM Intervention for AYAs With Cancer
NCT02414685	PHASE2	COMPLETED	First Line TIP in Poor Prognosis TGCTs.
NCT02624388	PHASE2	TERMINATED	Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)
NCT02689219	PHASE2	TERMINATED	Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
NCT02988843	PHASE2	TERMINATED	Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
NCT03081923	PHASE2	TERMINATED	Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors
NCT03194906	PHASE2	COMPLETED	Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
NCT03726281	PHASE2	WITHDRAWN	Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors
NCT03950830	PHASE2	COMPLETED	Disulfiram and Cisplatin in Refractory TGCTs.
NCT03960151	PHASE2	WITHDRAWN	Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
NCT04648826	PHASE1/PHASE2	WITHDRAWN	Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
NCT04791228	PHASE2	WITHDRAWN	A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
NCT05634785	PHASE2	COMPLETED	CD30 CAR for CD30+ NSGCT
NCT06470464	PHASE2	COMPLETED	Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BLEOMYCIN	4	5
2-MERCAPTOETHANESULFONIC ACID	4	2
BRENTUXIMAB VEDOTIN	4	2
TREMELIMUMAB	4	2
APREPITANT	4	1
DISULFIRAM	4	1
ETOPOSIDE PHOSPHATE	4	1
IFOSFAMIDE	4	1
MANNITOL	4	1
PALONOSETRON	4	1
PAZOPANIB	4	1
ROLAPITANT	4	1
SODIUM THIOSULFATE	4	1
SORBITOL	4	1
TENIPOSIDE	4	1
TETANUS TOXOID	4	1
URSODIOL	4	1
BINTRAFUSP ALFA	3	1
GUADECITABINE	3	1
KEYHOLE LIMPET HEMOCYANIN	3	1
RECOMBINANT HUMAN THROMBOPOIETIN	3	1
ZANZALINTINIB	3	1
GENISTEIN	2	1
CHEMBL3753202	0	1
CHEMBL4068768	0	1
CHEMBL4171277	0	1
CHEMBL5417591	0	1
CARBOPLATINE	0	1
EXELIXIS	0	1